NTRB News and Press, Nutriband Inc. From 12/18/25

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the ...

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precurs...

Banco Comercial Portugues, S.A. ADR (BPCGY) is expected to report $0.23 for Q3 2025 G-III Apparel Group LTD. (GIII) is expected to report $1.6 for Q3 2026 Ashtead Group plc ADR (ASHTY) is expected to report $4.55 for Q2 2026 Braze Inc. (BRZE) is expected to report $-0.27 for Q3 2026 ...

Leslie's Inc. (LESL) is expected to report $1.09 for Q4 2025 Banco Comercial Portugues, S.A. ADR (BPCGY) is expected to report $0.23 for Q3 2025 United Natural Foods Inc. (UNFI) is expected to report $0.39 for Q1 2026 Fortescue Metals Group Ltd ADR (FSUGY) is expected to report $0.58 ...

2025-11-24 09:45:00 ET Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Educ...

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the develop...

2025-10-28 10:58:39 ET Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product, ...

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the develop...

2025-10-27 10:00:16 ET Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the compan...

2025-10-27 07:18:00 ET More on Nutriband Nutriband announces exercise of warrants at $6.43 for gross proceeds of $5.31M Seeking Alpha’s Quant Rating on Nutriband Historical earnings data for Nutriband Financial information for Nutriband Read ...